EYPT EyePoint Pharmaceuticals
- 8.140
- +0.140+1.75%
EyePoint Pharmaceuticals News
EyePoint Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Director Hassan Fred
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Hassan Fred
EyePoint Pharmaceuticals | 8-K: Current report
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director DICICCO WENDY F
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director ANDO GORAN
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Zaderej Karen L.
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Lurker Nancy
EyePoint Pharmaceuticals | EFFECT: Others
EyePoint Pharmaceuticals | CORRESP: CORRESP
EyePoint Pharmaceuticals | UPLOAD: Others
EyePoint Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
EyePoint Pharmaceuticals | S-3: Registration statement for specified transactions by certain issuers
EyePoint Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
EyePoint Pharmaceuticals | 8-K: EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Lurker Nancy
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director GUYER DAVID R
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Duker Jay S.
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Lurker Nancy
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Zaderej Karen L.
EyePoint Pharmaceuticals | 8-K: Current report
Analysis
Price Target
No Data
No Data